Filing Details

Accession Number:
0001140361-10-022412
Form Type:
4
Zero Holdings:
No
Publication Time:
2010-05-20 13:00:00
Reporting Period:
2010-05-19
Filing Date:
2010-05-20
Accepted Time:
2010-05-20 16:15:58
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1061983 Cytokinetics Inc CYTK Pharmaceutical Preparations (2834) 943291317
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1288952 Michael Schmertzler C/O Credit Suisse
Eleven Madison Avenue
New York NY 10010
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $0.001 Disposition 2010-05-19 16,239 $3.00 4,403,913 No 4 S Indirect See Footnote 2
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnote 2
Footnotes
  1. Represents the average per share sale price.
  2. The post transaction share total of 4,403,913 is represented by the following: (a) 3,278,221 shares of Common Stock held by Credit Suisse First Boston Equity Partners, L.P.; (b) 916,345 shares of Common Stock held by Credit Suisse First Boston Equity Partners (Bermuda), L.P.; (c) 2,916 shares of Common Stock held by Credit Suisse First Boston U.S. Executive Advisors, L.P.; (d) 88,766 shares of Common Stock held by EMA Partners Fund 2000, L.P.; and (e) 117,665 shares of Common Stock held by EMA Private Equity Fund 2000, L.P. Such amounts include shares of Common Stock issuable upon exercise of warrants previously reported in May 2009. Mr. Schmertzler is a Managing Director of Aries Advisors, LLC, the sub-advisor to Credit Suisse First Boston Equity Partners, L.P. Mr. Schmertzler disclaims beneficial ownership of the shares held by entities affiliated with Credit Suisse except to the extent of his proportionate partnership or membership interest, if any, therein.